Introduction {#s1}
============

Papillary thyroid carcinoma (PTC) is the most common malignant tumor in endocrine organs, and its incidence has increased over the past decades [@pone.0036063-Xing1]. PTCs have characteristic genetic alterations leading to the activation of mitogen-activated protein kinase (MAPK) signaling pathway. Those include *RET/PTC* rearrangements and point mutations in *BRAF* and *RAS* family genes [@pone.0036063-Kondo1]. They are found in approximately 60--70% of all PTCs and rarely overlap in the same tumor [@pone.0036063-Frattini1]--[@pone.0036063-Soares1]. The lack of coexistence provides strong genetic evidence for the requirement of constitutively active MAPK signaling for development of PTC. However, the remaining 30--40% of PTC cases do not have genetic changes in these genes, suggesting that other factors may exist as a trigger to activate the MAPK pathway.

The *BRAF* mutation is the most prevalent genetic alteration in PTCs (44% on average) [@pone.0036063-Xing1]. The mutation in PTCs is almost exclusively a thymine-to-adenine transversion at nucleotide 1799 in exon 15, resulting in a valine-to-glutamic acid substitution at amino acid 600 (V600E) [@pone.0036063-Xing1]. This mutation is believed to produce a constitutively active kinase by disrupting hydrophobic interactions between residues in the activation loop and residues in the ATP binding site, allowing development of new interaction that fold the kinase into a catalytically competent structure [@pone.0036063-Wan1].

Many studies, but not all of them, have demonstrated the associations between this mutation and clinicopathological aggressiveness such as extrathyroidal invasion, lymph node metastasis, advanced stage, and recurrence [@pone.0036063-Xing1]. Indeed, transgenic mice overexpressing BRAF^V600E^ in thyroid cells develop invasive PTCs with some tall-cell features and poorly differentiated areas [@pone.0036063-Knauf1]. In addition, conditional expression of BRAF^V600E^ in the rat normal thyroid PCCL3 cells induced invasion and chromosomal instability, which was not observed in the same system with RET/PTC oncoprotein [@pone.0036063-Mitsutake1], [@pone.0036063-MesaC1].

Chromosomal aberrations have been reported at relatively low frequency in PTCs [@pone.0036063-Bauer1]--[@pone.0036063-Wreesmann3]. In these reports, comparative genomic hybridization (CGH) which provides a low resolution was used. However, two studies using array CGH, which enables a higher resolution depending on the number of probes, demonstrated a wide range of chromosomal aberrations [@pone.0036063-Unger1], [@pone.0036063-Finn1]. In contrast to CGH or array CGH, single nucleotide polymorphism array (SNP-A) as a molecular karyotyping tool has excellent resolution and allows us to detect copy number alteration (CNA) and also uniparental disomy (UPD) in the same experiment. The detection of UPD, also referred to as copy neutral loss of heterozygosity (CN-LOH), along whole genome is one of the advantages of SNP-A. The discovery of UPD in cancers has indicated that LOH is not necessarily due to loss of chromosomal material. In regions of UPD, portions of one of the chromosomes are lost and replaced by the exact copy of the other remaining chromosome, resulting in retention of two copies of genetic information but loss of polymorphic differences (both are from the same parent), which can be detected by SNP-A but not by conventional cytogenetic analysis such as CGH. UPD has been reported to be associated with both oncogenic mutations and inactivation of tumor suppressor genes in cancers [@pone.0036063-Soh1]. UPD may be an important mechanism in cancer development [@pone.0036063-Tuna1], [@pone.0036063-Makishima1]. To the best of our knowledge, there has been only one study using SNP-A for PTC; 10 cases of pediatric radiation-associated post-Chernobyl PTCs were analyzed using Affymetrix 50 K Mapping array [@pone.0036063-Stein1]. However, no significant regions of LOH were identified in this analysis. General sporadic PTCs have not been analyzed using SNP-A.

In the present study, we analyzed 25 Japanese sporadic PTCs with or without *BRAF^V600E^* mutation using Affymetrix Genome-Wide Human SNP Array 6.0 (SNP6.0) which gives much higher resolution (1.8 M probes) compared to the previous studies. This is the first report showing the presence of UPD in PTCs. We aimed to assess whether *BRAF* mutational status is associated with genomic instability and characteristic chromosomal aberrations represented by CNA and UPD. We also attempted to identify novel chromosomal portions that may contain genes involved in PTC pathogenesis.

Materials and Methods {#s2}
=====================

Patients and Tumor Tissues {#s2a}
--------------------------

Fresh tumor tissue samples were collected from 25 patients with sporadic PTC (mean±SD age 53.3±16.3 years old, range 18--81 years old; 84.0% women; no any pretreatment), snap-frozen in liquid nitrogen, and stored at −80°C until use. An appropriate written informed consent was obtained from each patient, and the study was approved by the ethics committees of Nagasaki University and Kuma Hospital. All patients had no history of radiation exposure. Clinical and pathological characteristics of the patients including UICC TNM staging are listed in [Table 1](#pone-0036063-t001){ref-type="table"}. Among 25 PTC samples, 11 had *BRAF^V600E^* mutation, 4 had *RET/PTC1* rearrangement, and 10 did not have any of the following oncogenic alterations: *HRAS*, *KRAS*, *NRAS*, and *BRAF* mutations; and *RET/PTC1* and *RET/PTC3* rearrangements. In this study, no new sequence data was generated.
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###### Clinicopthological data and genomic alterations in the 25 Japanese PTC cases.

![](pone.0036063.t001){#pone-0036063-t001-1}

  Case    BRAF*^V600E^*   RET/PTC1 rearrangement   CNA   AS-UPD(CN-LOH)   Percent of altered genome   Age   Sex   Tumor size (mm)   Histological type   pEx    pT     pN      M       Vessel invasion   Stage   Recurrence
  ------ --------------- ------------------------ ----- ---------------- --------------------------- ----- ----- ----------------- ------------------- ----- ------- ---- ---------- ----------------- ------- ------------
  T13          \+                   −               −          \+                    0.5              45     F          23                  p            0    1b--m   1a      0              −           III        −
  T15          \+                   −               −          −                     0.0              37     F          35                  p            2     4a     1a      0              −            I         −
  T17          \+                   −              \+          \+                   16.8              75     F          53              p+poorly         2     4a     1b   M1--lung        v+++          IVC        \+
  T21          \+                   −              \+          −                     1.2              63     F          23                  p            1      3     x       0              −           III        −
  T23          \+                   −               −          \+                    2.3              62     F          38                  p            2     4a     1b      0              −           IVA        −
  T24          \+                   −               −          −                     0.0              60     F          22                  p            1      3     0       0              −           III        −
  T25          \+                   −               −          −                     0.0              36     F          27                  p            1      3     0       0              −            I         −
  T30          \+                   −               −          −                     0.0              74     F          39                  p            1      3     0       0              −           III        −
  T45          \+                   −               −          −                     0.0              69     F          36              p+poorly         1      3     1a      0              −           III        −
  T53          \+                   −               −          −                     0.0              60     M          20                  p            1      3     1a      0             ND           III        −
  T58          \+                   −               −          −                     0.0              46     F          29                  p            x      x     1b      0              −           IVA        −
  T08           −                   \+              −          −                     0.0              22     F          15                  p            1      3     1b      0           v+, ly+         I         −
  T18           −                   \+              −          −                     0.0              18     F          33                  p            1      3     1b      0              −            I         −
  T19           −                   \+             \+          −                     1.8              36     F          20                  p            0     1b     x       0              −            I         −
  T20           −                   \+              −          −                     0.0              41     F          12                  p            0     1b     1b      0              −            I         −
  T05           −                   −               −          \+                    2.0              70     F          36                  p            0      2     1b      0             ND           IVA        −
  T06           −                   −               −          \+                    6.0              42     F          24                 fv            0      2     0       0             ND            I         −
  T07           −                   −               −          \+                    2.3              46     F           8                  p            1      3     x       0             ND           III        −
  T11           −                   −               −          −                     0.0              63     F          37                  p            1      3     1a      0             ND           III        −
  T27           −                   −               −          −                     0.0              49     F          24                  p            0     1b     1b      0             ND           IVA        −
  T32           −                   −              \+          −                     1.7              56     M          45                 fv            0      3     1b      0             ND           IVA        −
  T36           −                   −              \+          −                     0.3              58     M          20                 fv            1      3     1b      0             ND           IVA        −
  T47           −                   −               −          −                     0.0              68     F          20                  p            0     1b     1a      0             ND           III        −
  T48           −                   −              \+          −                     1.2              81     F          25                  p            1      3     x       0             ND           III        −
  T50           −                   −              \+          −                     3.7              56     M          65              p+poorly         1      3     1a      0              −           III        −

Using the UICC TNM classification.

Other abbreviations, F: female; M: male; p: papillary; fvp: follicular variant; ND: not described.

Genomic DNA Extraction and Mutation Screening for BRAF and RAS {#s2b}
--------------------------------------------------------------

DNA was extracted from the frozen tissues using QIAamp DNA mini kit (QIAGEN, Tokyo, Japan) according to the manufacturer's protocol. Common mutational hotspots of *BRAF* (exon 15) and *HRAS*, *KRAS* and *NRAS* (codons 12, 13, and 61) were examined by direct DNA sequencing. Primer sequences used for PCR and sequencing are listed in [Table S1](#pone.0036063.s003){ref-type="supplementary-material"}. PCR amplification was done using AmpliTaq Gold (Applied Biosystems, Life Technologies Japan, Tokyo, Japan). PCR products were treated with ExoSAP-IT PCR clean-up reagent (GE Healthcare Japan, Tokyo, Japan), and sequencing was performed with Big Dye Terminator sequencing kit version 3.1 (Applied Biosystems) on an ABI3100 automated sequencer (Applied Biosystems).

RET/PTC Rearrangement Screening {#s2c}
-------------------------------

For *RET/PTC* screening, RNA extraction and RT-PCR were done. Briefly, total RNA was extracted from the frozen tissues using ISOGEN (Nippon Gene, Tokyo, Japan) reagent according to the manufacturer's instruction. The RNA was then reverse transcribed using MMLV-RT (Applied Biosystems) and random hexamers to generate cDNA. Subsequent PCR amplification was performed using AmpliTaq Gold. Primer sequences are listed in [Table S1](#pone.0036063.s003){ref-type="supplementary-material"}.

Copy Number Detection and SNP Genotyping by High Resolution Genome-wide DNA Microarray {#s2d}
--------------------------------------------------------------------------------------

We performed high-resolution genome-wide DNA copy number detection and single nucleotide polymorphism (SNP) genotyping using Genome-Wide Human SNP Array 6.0 (SNP6.0) that interrogates 906,600 SNPs and 945,826 copy number probes, following the manufacturer's instructions (Affymetrix Japan, Tokyo, Japan). Array scanning and genotyping were performed using Affymetrix GeneChip Command Console (AGCC) and Birdseed v2 algorithm of Genotyping Console (GTC) 4.0 software (Affymetrix). As a quality control of the genotyping, Contrast QC value was calculated as implemented in the GTC 4.0. Genomic positions of the SNPs corresponded to the March 2006 human genome (hg18). Copy number and allele ratio analysis was performed by Partek Genomics Suite version 6.5 (Partek Inc., St. Louis, MO, USA). Reference generated from the intensities of pooled 52 normal Japanese sample profiles in our laboratory was used. The data sets were also used as a baseline to determine LOH. Genomic segmentation method was used to detect amplified or deleted segments using Partek Genomics Suite with stringent parameters (p≤0.0001, ≥20 markers, signal/noise ≥0.6), and only segments ≥100 probes were considered for further analysis to avoid false positive [@pone.0036063-Astolfi1].

UPD areas were also confirmed using Hidden Markov Model and Copy Number Analyser for GeneChip 3.0/Allele-specific Copy Number Analysis using anonymous References (CNAG/AsCNAR) as previously described (compared with 3--10 best fit normal references with the lowest SD) [@pone.0036063-Nannya1], [@pone.0036063-Yamamoto1]. Copy number variations (CNVs) seen in both our SNP6.0 analysis and the Database of Genomic Variants (DGV, <http://projects.tcag.ca/variation/>) were considered as tumor-unrelated CNVs and excluded from further analysis [@pone.0036063-Tiu1]. When run of homozygosity (ROH) was detected, telomeric lesions or interstitial defects ≥24.6 mega bases (Mb) were considered true acquired somatic UPD (AS-UPD), since small region of homozygosity can result from autozygosity or germline UPD [@pone.0036063-Tiu1]--[@pone.0036063-Dunbar1]. In a strict sense, however, AS-UPD (or CN-LOH) can only be confirmed by comparing tumor tissue with non-tumor tissue in one individual. Accordingly, the term "UPD" used in this study is rigorously equal to a relatively large segment region of ROH, although it is most likely AS-UPD.

Regions of CNA or UPD were cross-referenced with Refseq genes (<http://www.ncbi.nlm.nih.gov/RefSeq/>) and the CancerGene database (<http://cbio.mskcc.org/CancerGenes/Select.action>) [@pone.0036063-Higgins1].

Comparison of Genomic Instability and Statistical Analysis {#s2e}
----------------------------------------------------------

To estimate genomic instability, the length of each genomic alteration (CNA and UPD) was summed, and the total length was divided by 2,858,034,764 bases, which is the total length of human genome (hg18), to calculate the percentage of altered genome.

Differences between groups divided by the status of oncogenic mutations were examined for statistical significance with Kruskal-Wallis test.

Odds ratios and 95% confidence intervals for the association between the presence of chromosomal aberration(s) and clinicopathological parameters including *BRAF* mutational status were estimated using unconditional logistic regression models including age, tumor size, histological type, and stage.

Results {#s3}
=======

CNA and UPD in the Japanese PTCs {#s3a}
--------------------------------

We analyzed genomic DNA from 25 Japanese PTC tissues by SNP6.0. A genome-wide view of detected CNA and UPD is shown in [Figure 1](#pone-0036063-g001){ref-type="fig"} and summarized in [Table S2](#pone.0036063.s004){ref-type="supplementary-material"}. UPDs \>10 Mb and \<24.6 Mb were also included for reference although we cannot exclude the possibility that these UPDs are germline. However, all these short UPDs were observed along with long UPDs (≥24.6 Mb) in all the cases except one (T15, [Figure 1b](#pone-0036063-g001){ref-type="fig"}), suggesting that most of these short UPDs are likely to be acquired somatic UPD (AS-UPD) (see [Materials and Methods](#s2){ref-type="sec"} section). Nevertheless, the short UPDs were excluded from the further analyses due to uncertainty.

![Genome-wide view of detected CNA and UPD.\
Twenty-five PTCs (11 with *BRAF^V600E^*, 4 with *RET/PTC1*, and 10 without mutation in *HRAS*, *KRAS*, *NRAS*, *BRAF*, *RET/PTC1*, or *RET/PTC3*) were analyzed using Genome-Wide Human SNP Array 6.0. Green lines: amplifications, red lines: deletions, blue lines: large (≥24.6 Mb) interstitial UPD regions, gray lines: small interstitial UPD regions (at least 10 Mb but no more than 24.6 Mb), orange lines: telomeric regions of UPD. a, Chromosomal view. Each line represents an individual aberration. The extent of the aberration is represented along the length of the chromosome. b, Case (oncogene status)-chromosome plot, which provides at-a-glance view of all aberrations in a single case. The extent of the aberrations is ignored.](pone.0036063.g001){#pone-0036063-g001}

Japanese PTC samples are very heterogeneous concerning the number, size, and location of CNA/UPD. The majority of the cases showed a few or no CNA/UPD ([Figure 1b](#pone-0036063-g001){ref-type="fig"}), and interestingly, CNA and UPD were rarely overlapped in the same tumor. Seven cases (T17, T19, T21, T32, T36, T48, T50; 28%) showed CNA(s), and 6 (T05, T06, T07, T13, T17, T23; 24%) showed UPD(s) ([Table S2](#pone.0036063.s004){ref-type="supplementary-material"}, [Figure S1](#pone.0036063.s001){ref-type="supplementary-material"}, and [S2](#pone.0036063.s002){ref-type="supplementary-material"}). Only one case (T17; 4%) showed both CNA and UPD with a highly complex karyotype ([Table S2](#pone.0036063.s004){ref-type="supplementary-material"} and [Figure S1](#pone.0036063.s001){ref-type="supplementary-material"}). Thirteen (T08, T11, T15, T18, T20, T24, T25, T27, T30, T45, T47, T53, T58; 52%) showed neither CNA nor UPD. Regarding CNA, deletions tended to be more frequent than amplifications ([Figure 1](#pone-0036063-g001){ref-type="fig"}). Associations between CNA (deletion and amplification)/UPD and clinicopathological parameters including *BRAF* mutational status were estimated using unconditional logistic regression models. Only follicular variant (fv) histotype (vs. classic papillary) was weakly associated with deletion (Odds ratio = 15.6, 95% confidence interval: 0.75--795.4, p = 0.098) but note that only three fv cases were included in our analysis. No obvious correlation was found between chromosomal aberrations and any other parameters ([Table 1](#pone-0036063-t001){ref-type="table"}).

Comparison of the Japanese PTCs by the Status of Oncogenic Mutation {#s3b}
-------------------------------------------------------------------

CNA occurred in 2 PTCs with *BRAF^V600E^* (2/11, 18%), 1 with *RET/PTC1* (1/4, 25%), and 4 without oncogenic mutation (no *HRAS*, *NRAS*, *KRAS*, *BRAF^V600E^*, *RET/PTC1*, *RET/PTC3*) (4/10, 40%) ([Figure 1](#pone-0036063-g001){ref-type="fig"} and [Table 1](#pone-0036063-t001){ref-type="table"}). The most frequent and recurrent CNA was the deletion in chromosome 22; however, it was found in only 4 cases (4/25, 16%): 2 PTCs with *BRAF^V600E^*, 1 with *RET/PTC1*, and 1 with no mutation ([Figure 1](#pone-0036063-g001){ref-type="fig"}). No specific CNA was found in each oncogene group ([Figure 1](#pone-0036063-g001){ref-type="fig"}).

UPD was found in 3 PTCs with BRAF^V600E^ (3/11, 27%) and in 3 with no mutation (3/10, 30%) ([Figure 1](#pone-0036063-g001){ref-type="fig"} and [Table 1](#pone-0036063-t001){ref-type="table"}). We found 11 interstitial UPDs (range, 24.6--105.7 Mb) and 1 UPD extending to the telomere. These UPDs were not overlapped, except for small regions on chromosome 12q (T23 and T05) ([Figure 1](#pone-0036063-g001){ref-type="fig"} and [Figure S2](#pone.0036063.s002){ref-type="supplementary-material"}).

Interestingly, in oncogene-positive cases (*BRAF^V600E^* and *RET/PTC1*), tumors with CNA/UPD were less frequent (5/15, 33%), whereas tumors with CNA/UPD were more frequent in oncogene-negative cases (7/10, 70%).

Next, we also measured the degree of genomic instability using the percentage of altered genome ([Table 1](#pone-0036063-t001){ref-type="table"}). As shown in [Figure 2](#pone-0036063-g002){ref-type="fig"}, there was no statistical difference among three oncogene groups (no mutation, *BRAF^V600E^*, and *RET/PTC1*).

![The degree of genomic instability among three oncogene groups (wild-type, *BRAF^V600E^*, and *RET/PTC1*).\
Each dot represents the percentage of altered genome of each case. The length of each genomic alteration (CNA/UPD) was summed, and the total length was divided by 2,858,034,764 bases to calculate the percentage of altered genome. Horizontal line shows mean. T17 case had a highly complex karyotype and was the only case with distant metastasis/recurrence. There was no statistical difference among these groups.](pone.0036063.g002){#pone-0036063-g002}

Candidate Genes Involved in the Japanese PTC Pathogenesis {#s3c}
---------------------------------------------------------

To find important tumorigenic events in PTC, we searched for CNA/UPD that was commonly shared among the samples. As mentioned above, the only recurrent genomic aberration was the deletion on chromosome 22q in 4 samples (4/25, 16%), which was independent of the oncogene status ([Figure 1](#pone-0036063-g001){ref-type="fig"}). The 22q deletion was large, spanning a 34 Mb region and containing 66 genes registered at the CancerGenes database ([Table S3](#pone.0036063.s005){ref-type="supplementary-material"}), some of which are potential tumor suppressor genes (*TOP3B*, *CHEK2*, *NF2*, *LIF*, *DUSP18*, *TIMP3*, *XRCC6*, and *PPARA*).

Since constitutive activation of the MAPK pathway is thought to be critical for PTC development, we next searched for RAS family/MAPK pathway genes (at CancerGenes) and also PTC-related genes reported in literature within CNA/UPD regions, regardless of their frequency. Selected candidate genes are listed in [Table S4](#pone.0036063.s006){ref-type="supplementary-material"}.

Discussion {#s4}
==========

In the present study, we have performed SNP6.0 analyses using the Japanese PTC tissue samples. As far as we know, this is the first report using SNP6.0 for molecular karyotyping of PTCs and also demonstrating the occurrence of UPD. SNP6.0 contains 1.8 M probes and achieves ultra high resolution (1 copy number marker every 700 bp on average). Since this study is unpaired analysis, we used stringent parameters to avoid false positive and also the CNAG/AsCNAR algorithm (see [Materials and Methods](#s2){ref-type="sec"} section) which enables accurate determination of allele-specific copy number without using paired normal DNA as well as the sensitive detection of LOH (including UPD) even in the presence of up to 70--80% of normal cell contamination. Moreover, we also utilized public copy number variation (CNV) database because CNVs are common in a wide range of human individual genome, covering 1002 Mb (35% of the genome) (<http://projects.tcag.ca/variation/>). Indeed, we excluded most of the small regions that were overlapped with the CNVs in the database. We believe that we avoided false positive but probably had false negative areas, although they were small regions.

Of 25 PTC cases, our data demonstrate relatively stable karyotypes: 7 CNAs, 6 UPDs (one case has both CNAs and UPD), and 13 normal karyotypes, consistent with earlier studies using conventional CGH or low resolution array CGH [@pone.0036063-Bauer1]--[@pone.0036063-Wreesmann3]. However, two recent studies using higher resolution array CGH and SNP-A reported chromosomal aberrations in all analyzed samples [@pone.0036063-Unger1], [@pone.0036063-Stein1]. Although CNV was not taken into consideration in these analyses, there were obvious differences among 3 studies including ours. Unger et al. demonstrated nearly whole loss of chromosome 17, 19, and 22 in most of adult *RET/PTC*-negative cases, which is not consistent with our data, and also loss of chromosome 6, 9p, and 13 in childhood cases, which is not matched to the study by Stein et al. We do not have any feasible explanation to solve this discrepancy. This might be due to ethnic variations.

Japanese PTCs have some distinct characteristics: the vast majority are low risk tumors with classic papillary morphology and higher prevalence of the *BRAF* mutation than in PTCs in western countries [@pone.0036063-Kumagai1]--[@pone.0036063-Zuo1]. These characteristics are presumably due to high iodine intake in Japanese population [@pone.0036063-FeldtRasmussen1]--[@pone.0036063-Guan1]. There have been a large number of publications reporting the relationship between *BRAF^V600E^* mutation and clinicopathological aggressiveness (reviewed in [@pone.0036063-Xing1]). *In vivo* and *in vitro* studies have also indicated that *BRAF^V600E^* drives aggressiveness and genomic instability [@pone.0036063-Mitsutake1], [@pone.0036063-MesaC1]. However, a recent study analyzing more than 600 Japanese patients in a single institution has demonstrated extremely good prognosis and no correlation of the *BRAF* mutational status with clinicopathological aggressiveness [@pone.0036063-Ito1]. This is in line with our results: low prevalence of CNA/UPD and no relationship between *BRAF* status and genomic instability in the Japanese PTCs. Further studies using samples from different ethnicities are needed.

It is of great interest that CNA and UPD were rarely overlapped in the same tumor. Five tumors with UPD had no CNA; six tumors with CNA had no UPD; only one tumor, T17 had both CNA and UPD. T17 was the only case with distant metastasis (lung), prominent vascular invasion, and recurrence. Along with highly complicated genomic aberrations, T17 is the end stage of the disease and may be exceptional. Thus, Japanese PTCs may be classified into three distinct groups: CNA^+^, UPD^+^, and no chromosomal aberrations, suggesting that different ways of acquiring genomic instability exist in PTCs. The frequency of CNA/UPD was higher in oncogene-negative cases (70%) than in oncogene-positive cases (33%), suggesting that chromosomal aberrations (or affected gene sets) may play a role in the development of PTC, especially in oncogene-negative tumors, albeit not statistically significant (Fisher's exact test, odds ratio = 4.667, 95% confidence interval: 0.83--26.25, p = 0.11). This implies that there may be distinct mechanisms for PTC development through oncogenic mutation and/or chromosomal instability.

We tried to identify novel chromosomal regions/genes involved in PTC pathogenesis, depending on mutational status of the oncogenes. However, the pattern of CNA/UPD in the Japanese cases was very heterogenous. We only found the 22q deletion as a recurrent region, which is consistent with previous studies [@pone.0036063-Singh1]--[@pone.0036063-Wreesmann3]. However, the 22q deletion was found in only 4 cases, suggesting that it may be difficult to find specific chromosomal aberrations that contain responsible genes for PTC development even though SNP6.0 was utilized. Furthermore, the presence of the 22q deletion was independent of the oncogene status. We selected candidate genes from the 22q area and other CNA/UPD regions using the CancerGenes database. Among the selected genes in the 22q area, *CHEK2* [@pone.0036063-Cybulski1], *LIMK2* [@pone.0036063-Hsu1], and *TIMP3* [@pone.0036063-Anania1] have already been reported to be deleted/down-regulated in thyroid cancer; the 22q deletion may play a role in thyroid carcinogenesis. Regarding the selected genes in other CNA/UPD areas, the *AKT3*/*PIK3CA* pathway [@pone.0036063-Viglietto1], [@pone.0036063-Xing2], the *KRAS*/*RAP1B*/*RAP1GAP*/*BRAF* pathway [@pone.0036063-Zuo2], [@pone.0036063-Nellore1], and the *VEGFC* pathway [@pone.0036063-Siironen1], [@pone.0036063-Hung1] have been known to participate in thyroid carcinogenesis/cancer progression. However, none of them is universal in PTCs.

In conclusion, we report for the first time the results of genome-wide molecular karyotyping using SNP6.0 concomitant with the analysis of oncogene mutational status in PTCs. The Japanese PTCs showed relatively stable karyotypes: approximately 1/4 of CNA, 1/4 of UPD, and 1/2 of no aberrations. We also demonstrate for the first time that UPD as a form of genomic instability may play a role in PTC development.
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**CNA regions identified using PartekGS software.** CN: smoothed copy number is plotted, AsCN: allele-specific copy number analysis in which each allele is plotted separately, AR: allele ratio pattern.
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**Whole-genome view of 5 PTC cases with UPD generated by CNAG/AsCNAR.** CN: linear copy number smoothed over 10 SNPs is plotted in chromosomal order along the horizontal axis (chromosome 1 on the left, chromosome 22 on the right), Hetero: green bars indicate heterozygous call, AsCN: allele-specific copy number analysis in which each allele is plotted separately. Blue box represents interstitial UPD (≥24.6 Mb); Orange box represents telomeric UPD.
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Chromosomal aberrations in Japanese PTCs.
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CancerGenes located in recurrent chromosome 22q deletion.
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RAS family/MAPK pathway genes from CancerGenes database and PTC-related genes located in the CNA/UPD region.
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